Consensus ARS Pharmaceuticals, Inc.

Stocks

SPRY

US82835W1080

Biotechnology & Medical Research

Market Closed - Nasdaq 21:00:00 01/10/2026 BST			5-day change	1st Jan Change
4.120 ^USD	-4.41%		-0.72%	-64.64%

08-13	ARS Pharmaceuticals Q2 Net Loss Widens, Revenue Rises	MT
08-13	ARS Pharmaceuticals, Inc., Q2 2026 Earnings Call, Aug 13, 2026

Evolution of the Average Target: ARS Pharmaceuticals, Inc.

Evolution of the Target Price: ARS Pharmaceuticals, Inc.

Changes in Analyst Recommendations: ARS Pharmaceuticals, Inc.

60272d901a07839.bulFEf1fwnm3_ciXvs_2noRit-T6llu56ntpc9hBvEY.F54Mfp5s9wrmk5L_iPmT5PM9h6-2_AHzhh49J74KihYe2w9OyQCECvSrnQ~38a80cb2b0dbc763f8cc12eb15001158

Analysts' recommendations: ARS Pharmaceuticals, Inc.

04/09/25	Roth Capital Initiates ARS Pharmaceuticals at Buy With $40 Price Target	MT
10/02/25	Oppenheimer Initiates ARS Pharmaceuticals at Outperform	MT
20/08/24	Cantor Fitzgerald Initiates ARS Pharmaceuticals at Overweight With $30 Price Target	MT
13/08/24	Raymond James Upgrades ARS Pharmaceuticals to Strong Buy From Outperform, Adjusts Price Target to $22 From $18	MT
25/07/24	Raymond James Starts ARS Pharmaceuticals With Outperform Rating	MT
05/03/24	Leerink Partners Upgrades ARS Pharmaceuticals to Outperform From Market Perform, Raises Price Target to $18 From $6	MT
20/02/24	William Blair Upgrades ARS Pharmaceuticals to Outperform From Market Perform	MT
06/02/24	Wedbush Raises ARS Pharmaceuticals' PT to $19 From $13 After Model Adjustments, Keeps Outperform Rating	MT
13/11/23	Wedbush Raises ARS Pharmaceuticals' PT to $13 From $5, Says Market Opportunity Intact; Maintains Outperform Rating	MT
20/09/23	William Blair Downgrades ARS Pharmaceuticals to Market Perform From Outperform	MT
21/06/23	Wedbush Trims ARS Pharmaceuticals' PT to $15 From $17, Adjusts US, EU Launch Estimates, Lowers Peak Penetration for neffy/Anaphylaxis in US; Keeps Outperform Rating	MT
31/01/23	Wedbush Initiates ARS Pharmaceuticals at Outperform With $10 PT, Says Neffy Intranasal Spray Set to Shake Up Epinephrine Market	MT
04/01/23	William Blair Initiates ARS Pharmaceuticals With Outperform	MT
13/12/22	SVB Securities Initiates ARS Pharmaceuticals With Outperform Rating, Price Target is $14	MT
16/05/22	Stifel Adjusts Price Target on Silverback Therapeutics to $5 From $6, Reiterates Hold Rating	MT
04/04/22	Goldman Sachs Downgrades Silverback Therapeutics to Neutral From Buy, Adjusts Price Target to $3.50 From $25	MT
01/04/22	JonesTrading Downgrades Silverback Therapeutics to Hold From Buy	MT
01/04/22	SVB Leerink Downgrades Silverback Therapeutics to Market Perform from Outperform, Adjusts Price Target to $1.80 from $25	MT
01/04/22	HC Wainwright Downgrades Silverback Therapeutics to Neutral from Buy	MT
01/04/22	Stifel Downgrades Silverback Therapeutics to Hold from Buy, Adjusts Price Target to $6 from $32	MT
12/11/21	SVB Leerink Adjusts Silverback Therapeutics' Price Target to $25 From $42, Keeps Outperform Rating	MT
16/08/21	Silverback Therapeutics : SVB Leerink Adjusts Silverback Therapeutics' Price Target to $49 from $46, Keeps Outperform Rating	MT
27/05/21	Silverback Therapeutics : JonesTrading Starts Silverback Therapeutics at Buy With $50 Price Target	MT
24/05/21	Silverback Therapeutics : SVB Leerink Adjusts Price Target on Silverback Therapeutics to $46 From $49, Maintains Outperform Rating	MT
06/04/21	Silverback Therapeutics : SVB Leerink Adjusts Price Target on Silverback Therapeutics to $49 From $40, Maintains Outperform Rating	MT

More recommendations

Other Biotechnology & Medical Research

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	ARS PHARMACEUTICALS, INC.					+446.12%
	WUXI APPTEC CO., LTD.					+11.79%
	ARGENX SE					+23.73%
	LONZA GROUP AG					+22.76%
	IQVIA HOLDINGS INC.					+10.75%
	REVOLUTION MEDICINES, INC.					+25.05%
	BEONE MEDICINES AG					+20.83%
	CELLTRION, INC.					+45.83%
	WUXI BIOLOGICS (CAYMAN) INC.					+3.91%
	INSMED INCORPORATED					+82.1%
	Average					+69.29%
	Weighted average by Cap.					+24.00%